Cardiovascular effects of equi-antiarrhythmic doses of alprenolol (a beta-adrenergic receptor antagonist) diphenylhydantoin and procainamide.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000605:Amino Alcohols / Q000494:pharmacology*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects; D004285:Dogs; D004562:Electrocardiography; D006439:Hemodynamics / Q000187:drug effects*; D010672:Phenytoin / Q000494:pharmacology*; D011342:Procainamide / Q000494:pharmacology*; D013565:Sympatholytics / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D000889:Anti-Arrhythmia Agents; D013565:Sympatholytics; D010672:Phenytoin; D011342:Procainamide